Mutz Christopher 4
4 · ANI PHARMACEUTICALS INC · Filed Feb 17, 2026
Research Summary
AI-generated summary of this filing
ANI Pharmaceuticals Head of Rare Disease Christopher Mutz Sells Shares
What Happened Christopher Mutz, Head of Rare Disease at ANI Pharmaceuticals (ANIP), disposed of a total of 12,608 shares in mid-February 2026. The filing reports an open-market sale of 7,032 shares on 2026-02-12 for a weighted average price of $76.55 (proceeds $538,300). In addition, 3,173 shares (2/12) and 2,403 shares (2/14) were surrendered/withheld to cover tax obligations at prices of $76.70 and $77.36 (proceeds/value shown as $243,369 and $185,896). Combined proceeds/values reported across all dispositions equal $967,565. These transactions are sales/tax-withholdings (not purchases), so they are routine disposals rather than fresh insider buys.
Key Details
- Transaction dates: Feb 12, 2026 (open-market sale and one tax-withholding) and Feb 14, 2026 (tax-withholding).
- Open-market sale: 7,032 shares at a weighted average $76.55 (range $75.43–$76.92 across multiple trades).
- Tax-withholding disposals: 3,173 shares at $76.70 and 2,403 shares at $77.36 (reported as payments to cover tax liability).
- Total shares disposed: 12,608; total reported proceeds/values: $967,565.
- Footnotes: tax-withheld shares were exempt under Rule 16(b)-3 for vesting of restricted stock (footnotes reference vesting of 6,202 shares granted Feb 18, 2025 and 4,697 shares granted Feb 16, 2024). The open-market sales were effected under a Rule 10b5-1 trading plan adopted June 16, 2025.
- Shares owned after transaction: not specified in the information provided in this summary.
- Filing: Form 4 filed Feb 17, 2026 reporting the above transactions.
Context
- The filing shows a mix of routine tax-withholding (surrendered shares to cover taxes on vested restricted stock) and planned open-market sales under a 10b5-1 plan. Tax-withholdings are standard when restricted shares vest and are generally treated as non-discretionary, exempt transfers under Rule 16(b)-3. The 10b5-1 plan indicates the open-market sales were made under a pre-established trading plan rather than ad-hoc trading by the insider.
Insider Transaction Report
- Tax Payment
Common Stock
[F1]2026-02-12$76.70/sh−3,173$243,369→ 99,598 total - Sale
Common Stock
[F2][F3]2026-02-12$76.55/sh−7,032$538,300→ 92,566 total - Tax Payment
Common Stock
[F4]2026-02-14$77.36/sh−2,403$185,896→ 90,163 total
Footnotes (4)
- [F1]Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 6,202 shares of restricted stock, the grant of which was previously reported on February 18, 2025.
- [F2]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2025.
- [F3]The shares were sold in multiple trades at prices ranging from $75.43 to $76.92. The price reported above reflects the weighted average sales price.
- [F4]Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 4,697 shares of restricted stock, the grant of which was previously reported on February 16, 2024.